Wong et al. described a partial response to lorlatinib (third generation) in a patient with ALK-positive IMT, who previously received prednisolone, eretrectinib and adriamycin-ifosfamide. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.